drugset
drugset / Trial / NCT04281745

Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®

NCT04281745 ↗

Phase 4 Unknown 200 enrolled Medy-Tox
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the long-term safety and efficacy of CORETOX in the treatment of moderate to severe glabellar lines.

Timeline

Start
2019-10-17
Primary completion
2020-06-17
Completion
2022-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject CORETOX Inj Unknown 20 iu Intramuscular

Indications

No indication recorded.